Advanced Bladder Cancer For patients with advanced disease, platinum-basedcombination chemotherapyhas been the first-line treatment for decades, with cisplatin-based treatments yielding a better overall survival than carboplatin-based combinations (12-15 months vs. 9 months).62,63However most patients pr...
Tumor immune microenvironment dynamics and outcomes of prognosis in non-muscle-invasive bladder cancer.[Journal Article] Cancer Sci. 2024 Oct 11 [Online ahead of print]Kamitani R, Tanaka N, … Oya MCS Agents that target PD-1 and PD-L1 have been developed in the treatment of bladder cancer ...
PrognosisBCG (Bacillus of Calmette Guerin) has been used for more than 20 years and is currently the most active agent for superficial bladder cancer therapy. Intravesical BCG therapy is effective in prophylaxis after transurethral resection of papillary tumours and in the treatment of carcinoma in ...
Kalman Unveils Insights on Thyroid Cancer Prognosis and Treatments Gupta Explores Sacituzumab Govitecan in Advanced Breast Cancer Treatment The Impact of T-DXd in HER2-Positive Breast Cancer Opinions on Treatment Split for Prominent Questions in Bladder Cancer Gupta Discusses T-DM1’s Role in H...
Additionally, we aimed to anticipate the impact of these values on the diagnosis, prognosis, and treatment response of the disease. This study is the first to investigate the prognostic value of serum fibronectin and its genetic variations in the context of BCG treatment for NMIBC....
BCG-RIVM strain was used in many treatment protocols for non-muscle invasive bladder cancer only as induction courses. Cho et al. (Anticancer Res 2012) compared BCG-RIVM induction and 'standard' maintenance (Lamm et al., J Urol. 2000) to mitomycin C. They found no statistically significant ...
Graph illustrating effect of intravesical BCG on renal function during treatment and following discontinuation Full size imageDiscussion Urothelial carcinoma is the eleventh most frequent cancer in women with mean age of 60 years and rising incidence in over 50 years [2]. NMIBC accounts for 75–90%...
Disease progression includes the development of muscle-invasive disease, which is associated with a poorer prognosis [6] and usually warrants radical treatment with cystectomy (removal of the urinary bladder) or irradiation. Various intravesical therapies (instillation of agents into the urinary bladder)...
Objective: To review the outcome of all superficial transitional cell (TCC) bladder cancer treated with intravesical Bacille Calmette-Guerin (BCG) at one institution and, in particular, the prognosis for those patients who gained little benefit from BCG therapy.Patients and Methods: The notes of 12...
BCG was first introduced into clinical use in urology in 1976 and remains the most effective form of intravesical treatment for non-muscle-invasive bladder cancer (NMIBC). Despite this successful history, BCG therapy is internationally underutilized and practice patterns of BCG administration vary ...